SCHEDULE 13G/A: Alger Associates, Inc. Amends Significant Stake in Forte Biosciences, Maintaining 14.2% Beneficial Ownership

Alger Associates, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 14.2% beneficial ownership stake in Forte Biosciences, Inc. as of March 31, 2025.

Summary

• Alger Associates, Inc. filed an Amendment No. 5 to Schedule 13G with the SEC, updating its beneficial ownership in Forte Biosciences, Inc.
• As of March 31, 2025, Alger Associates, Inc. beneficially owns 910,609 shares of Forte Biosciences, Inc. Common Stock.
• This ownership represents 14.2% of the total class of securities outstanding.
• Alger Associates, Inc. holds sole voting power and sole dispositive power over all 910,609 shares.
• The securities are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC, a wholly-owned subsidiary of Alger Associates, Inc.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Forte Biosciences, Inc.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's operational or financial performance.

Positives

• The filing indicates continued significant institutional investment in Forte Biosciences, Inc. by Alger Associates, Inc., a notable asset manager.
• The reporting person certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive investment stance.

Risks

• While the filing states no intent to influence control, a large beneficial ownership stake could still be perceived as a potential factor in future corporate governance discussions, though the document explicitly disclaims this intent.

Future Outlook

The document is a beneficial ownership report and does not provide any forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future performance or strategic outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure for large institutional investors, indicating that Alger Associates, Inc. continues to hold a significant passive stake in Forte Biosciences, Inc. on behalf of its investment management clients. Such disclosures provide transparency into institutional holdings within the biotechnology or pharmaceutical sector, where Forte Biosciences operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake and its stated intent not to influence control, which can offer clarity on the shareholder base.

Key Dates

Keywords

Forte Biosciences, Alger Associates, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing, investment management